Drug intelligence / Profile preview

VS-367

Development stage: Preclinical
Lead developer: Vasa Therapeutics
Modality: Peptides, Small Molecules

Overview

VS-367 is a synthetic peptide drug candidate initially developed by Vasa Therapeutics. It is being investigated for use in cardiovascular diseases, endocrinology and metabolic diseases, and urogenital diseases. The primary active indications under preclinical development include chronic kidney disease, obesity, and peripheral arterial disease. As of the latest update (May 2025), the drug has not advanced beyond preclinical studies. Detailed mechanism of action or specific molecular targets have not been disclosed publicly[1].

Beyond the preview

Go deeper on VS-367.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-367.

Explore the full profile